Your browser doesn't support javascript.
loading
Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy-Do Different Software Solutions Deliver Comparable Results?
Hartrampf, Philipp E; Heinrich, Marieke; Seitz, Anna Katharina; Brumberg, Joachim; Sokolakis, Ioannis; Kalogirou, Charis; Schirbel, Andreas; Kübler, Hubert; Buck, Andreas K; Lapa, Constantin; Krebs, Markus.
Afiliação
  • Hartrampf PE; Department of Nuclear Medicine, University Hospital Würzburg, 97080 Würzburg, Germany.
  • Heinrich M; Department of Nuclear Medicine, University Hospital Würzburg, 97080 Würzburg, Germany.
  • Seitz AK; Department of Urology and Paediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany.
  • Brumberg J; Department of Nuclear Medicine, University Hospital Würzburg, 97080 Würzburg, Germany.
  • Sokolakis I; Department of Urology, Martha-Maria Hospital Nuremberg, 90491 Nuremberg, Germany.
  • Kalogirou C; Department of Urology and Paediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany.
  • Schirbel A; Department of Nuclear Medicine, University Hospital Würzburg, 97080 Würzburg, Germany.
  • Kübler H; Department of Urology and Paediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany.
  • Buck AK; Department of Nuclear Medicine, University Hospital Würzburg, 97080 Würzburg, Germany.
  • Lapa C; Department of Nuclear Medicine, University Hospital Würzburg, 97080 Würzburg, Germany.
  • Krebs M; Nuclear Medicine, Medical Faculty, University of Augsburg, Stenglinstrasse 2, 86156 Augsburg, Germany.
J Clin Med ; 9(5)2020 May 08.
Article em En | MEDLINE | ID: mdl-32397223
ABSTRACT
(1)

Background:

Prostate-specific membrane antigen (PSMA)-derived tumour volume (PSMA-TV) and total lesion PSMA (TL-PSMA) from PSMA PET/CT scans are promising biomarkers for assessing treatment response in prostate cancer (PCa). Currently, it is unclear whether different software tools for assessing PSMA-TV and TL-PSMA produce comparable results. (2)

Methods:

68Ga-PSMA PET/CT scans from n = 21 patients with castration-resistant PCa (CRPC) receiving chemotherapy were identified from our single-centre database. PSMA-TV and TL-PSMA were calculated with Syngo.via (Siemens) as well as the freely available Beth Israel plugin for FIJI (Fiji Is Just ImageJ) before and after chemotherapy. While statistical comparability was illustrated and quantified via Bland-Altman diagrams, the clinical agreement was estimated by matching PSMA-TV, TL-PSMA and relative changes of both variables during chemotherapy with changes in serum PSA (ΔPSA) and PERCIST (Positron Emission Response Criteria in Solid Tumors). (3)

Results:

Comparing absolute PSMA-TV and TL-PSMA as well as Bland-Altman plotting revealed a good statistical comparability of both software algorithms. For clinical agreement, classifying therapy response did not differ between PSMA-TV and TL-PSMA for both software solutions and showed highly positive correlations with BR. (4)

Conclusions:

due to the high levels of statistical and clinical agreement in our CRPC patient cohort undergoing taxane chemotherapy, comparing PSMA-TV and TL-PSMA determined by Syngo.via and FIJI appears feasible.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: J Clin Med Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: J Clin Med Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha